Mostrar 1 - 20 resultats de 20 per cerca '"Argentina"', hora de la petició: 0.32sec Refinar resultats
  1. 1
    “…The aim of this study was to explore individual, social-structural and environmental factors associated with healthcare avoidance among TG women in Argentina. METHODS: Data were derived from a 2013 nation-wide, cross-sectional study involving TG women in Argentina. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Factors associated with healthcare avoidance among transgender women in Argentina
  2. 2
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care
  3. 3
    “…INTRODUCTION: The Argentinean AIDS Program estimates that 110,000 persons are living with HIV/AIDS in Argentina. Of those, approximately 40% are unaware of their status, and 30% are diagnosed in advanced stages of immunosuppression. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Routine HIV Testing among Hospitalized Patients in Argentina. Is It Time for a Policy Change?
  4. 4
    “…The aim of this study was to explore factors associated with engagement with the Gender Identity Law among transwomen living in Argentina. METHODS: Data were derived from a 2013 nationwide, cross-sectional study involving transwomen in Argentina. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Towards Full Citizenship: Correlates of Engagement with the Gender Identity Law among Transwomen in Argentina
  5. 5
    “…Purpose: In Argentina, transgender women face a disproportionately high prevalence of HIV infection (34%). …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    High Willingness to Use HIV Pre-Exposure Prophylaxis Among Transgender Women in Argentina
  6. 6
    “…BACKGROUND: In Argentina, HIV prevalence among transgender women (TGW) has been reported at 34%. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Home-based HIV testing: Using different strategies among transgender women in Argentina
  7. 7
    “…To redesign an existing system for two HIV clinics in Argentina, we employed a three-phase approach of exploration, participatory design, and prototyping. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Redesigning an Electronic Health Record in Argentina to Improve Comprehensive Health Care and Clinical Research
  8. 8
    “…CONCLUSIONS: This is the first study in Argentina, to our knowledge, describing the prevalence of cryptococcosis and usefulness of CrAg screening. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay
  9. 9
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Assessing the Underestimation of HIV Risk Infection among Young Men Who Have Sex with Men in Argentina
  10. 10
    “…In Argentina, transgender women (TGW) have a high HIV prevalence (34%). …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study
  11. 11
    “…An estimated 110,000 individuals are HIV-infected in Argentina; of these, 70% have been diagnosed and 54% were linked to care. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial
  12. 12
    “…The aim of this study was to describe clinical characteristics and outcomes in a cohort of patients hospitalized with SARS-CoV-2 in Argentina. METHODS: Multicenter prospective cohort study of ≥18 years-old patients with confirmed SARS-CoV-2 infection consecutively admitted to 19 hospitals in Argentina. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective study
  13. 13
    “…The study was a cluster-randomised clinical trial entitled Conexiones y Opciones Positivas en la Argentina 2 (COPA2) and was registered at clinicaltrials.gov, NCT02846350. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV care
  14. 14
    “…In multivariate analysis, only ARS and baseline VL > 100,000 copies/mL remained independently associated; HR: 8.44 (95% CI 0.97-73.42) and 9.44 (95% CI 1.38-64.68), respectively. CONCLUSIONS: In Argentina, PHI is associated with significant morbidity. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters
  15. 15
    “…METHODS: Antiretroviral-naïve patients ≥18 years who started first HAART after January 1, 2000 in Caribbean, Central and South America Network (CCASAnet) sites in Argentina, Brazil, Honduras, Mexico, and Peru were included. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Use of Third Line Antiretroviral Therapy in Latin America
  16. 16
    “…FINDINGS: Study enrolment began on Sept 22, 2020, in Pakistan, Nov 6, 2020, in Mexico, Dec 2, 2020, in Russia and Chile, and Dec 17, 2020, in Argentina; 150 endpoint cases were reached on Jan 15, 2021, triggering the final primary efficacy analysis. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
  17. 17
    “…Eleven participants were selected by purposive sampling in Argentina until data saturation was reached. A content analysis was performed. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Exploring the Decision-Making Process of People Living with HIV Enrolled in Antiretroviral Clinical Trials: A Qualitative Study of Decisions Guided by Trust and Emotions
  18. 18
    “…RESULTS: Of 191 trial participants enrolled in Argentina, 172 had baseline and follow-up measurements and were included. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial
  19. 19
    “…METHODOLOGY: Antiretroviral-naïve patients > = 18 years who started HAART between 1996 and 2007 and had at least one follow-up visit from sites in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru were included. …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Text
    Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America
  20. 20
    “…METHODS: we conducted a double-blind, randomized, placebo-controlled trial to assess efficacy and safety of EpAbs (INM005) in hospitalized adult patients with moderate and severe COVID-19 pneumonia in 19 hospitals of Argentina. Primary endpoint was improvement in at least two categories in WHO ordinal clinical scale at day 28 or hospital discharge (ClinicalTrials.gov number NCT04494984). …”
    Obtenir text complet
    Obtenir text complet
    Obtenir text complet
    Online Article Text
    RBD-specific polyclonal F(ab´)(2) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial
Eines de cerca: Obtenir subscripció RSS